Phase II trial of Cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study.
Authors
Rembielak, AgataJain, Pooja
Jackson, Andrew
Green, Matthew M L
Santorelli, Gillian R
Whitfield, Gillian A
Crellin, A
Garcia-Alonso, A
Radhakrishna, G
Cullen, James N
Taylor, Benjamin
Swindell, Ric
West, Catharine M L
Valle, Juan W
Saleem, Azeem
Price, Patricia M
Affiliation
Academic Department of Radiation Oncology, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United KingdomIssue Date
2014-02
Metadata
Show full item recordAbstract
Preclinical data have indicated the anti-epidermal growth factor receptor (EGFR) agent cetuximab (Erbitux) as a radiosensitizer in pancreatic cancer, but this has not been specifically addressed in a clinical study. We report the results of an original study initiated in 2007, where cetuximab was tested with radiotherapy (RT) alone in locally advanced pancreatic cancer in a phase II trial (PACER).Citation
Phase II trial of Cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study. 2014, 7 (1):55-64 Transl OncolJournal
Translational OncologyPubMed ID
24772208Type
ArticleLanguage
enISSN
1936-5233Collections
Related articles
- A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma.
- Authors: Cetin V, Piperdi B, Bathini V, Walsh WV, Yunus S, Tseng JF, Whalen GF, Wassef WY, Kadish SP, Fitzgerald TJ, Mikule C, Wang Y, Grossman SR
- Issue date: 2013 Jul
- Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
- Authors: Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group.
- Issue date: 2010 Jun
- Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
- Authors: Fiore M, Trodella L, Valeri S, Borzomati D, Floreno B, Ippolito E, Trecca P, Trodella LE, D'Angelillo RM, Ramella S, Coppola R
- Issue date: 2015 Dec 15
- Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
- Authors: Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA
- Issue date: 2011 Aug 1
- A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
- Authors: Arnoletti JP, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, Christein J, Oster R, Buchsbaum DJ, Vickers SM
- Issue date: 2011 Apr